Drug Discovery Services Market Outlook (2023 to 2033)

The global drug discovery services market size is projected to garner significant growth from 2023 to 2033. According to the research report published by FMI, the global market is anticipated to surpass a valuation of US$ 19.7 billion in 2023. It is likely to hit a valuation of US$ 76.5 billion by 2033. The market is projected to exhibit a captivating CAGR of 14.5% from 2023 to 2033.

New drugs are continuously required to address the various unmet medical needs. Several diseases, including neurodegenerative, cancer, rare genetics, and cardiovascular diseases still lack effective treatment. The emergence of new diseases is spiraling the demand for new drugs. Drug discovery services are expected to increase multifold due to the growing development and discovery of novel drugs.

Drug discovery requires substantial resources and time. As drug discovery becomes complex, the demand for specialized expertise across various scientific disciplines rises. Experts from toxicology, medicinal chemistry, pharmacology, and formulation development usually engage in discovering new drugs. Outsourcing these services can reduce costs and time for research institutions and pharmaceutical companies. The outsourced drug delivery services market provides access to specialized infrastructure and expertise, without any high investments.

Several pharmaceutical, biopharmaceutical, and medical device businesses devote significant resources to developing new medications and technologies. The pharmaceutical sector spends a lot of money on research and development (R&D). The research and development pharmaceutical industry brings high-quality, innovative goods to market. The top pharma companies are enhancing their R&D efficiencies through massive R&D investments to reap long-term benefits.

Initiatives for rare diseases and orphan drug research drive new income streams in the market. However, stringent rules regulating drug research and animal testing may limit market expansion to some extent. Moreover, drug discovery service companies still need to deal with the problem of a scarcity of trained employees.

Attributes Details
Drug Discovery Services Market Share (2022) US$ 17.5 billion
Drug Discovery Services Market Share (2023) US$ 19.7 billion
Drug Discovery Services Market Share (2033) US$ 76.5 billion
Drug Discovery Services Market Share (2023 to 2033) 14.5%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Drug Discovery Services Market Historical Analysis (2018 to 2022) Vs. Forecast Outlook (2023 to 2033)

In 2022, the global drug discovery services market size stood at US$ 17.5 billion. The market share is expanding rapidly due to the rising market dynamics for pharmaceuticals. Technical developments are likely to amplify market development. An increase in the adoption of novel methodologies for discovery is observed. Escalating demand for generic medications and an increase in patients expiring, all contribute to rising drug distribution.

The increased research and development in the pharmaceutical industry bolster the market’s growth prospects. The evolution of the healthcare industry combined with the rise in demand for generic medications augments the demand for drug discovery services. The rising geriatric population, and technical developments in drug discovery services, all accelerate the market's growth. Additionally, the growing pharmaceutical sector and a surge in contract development services aid market expansion. Growing manufacturing companies that are promoting drug discovery operations boost sales of drug discovery services.

Other factors that positively influence drug discovery trends include:

  • An increase in awareness about chronic diseases
  • A surge in the patient pool
  • Increasing unmet medical needs
  • Increasing funding and reimbursement initiatives

Category-wise Insights

Why do Pharmaceutical Companies Hold a Huge Chunk of the Market Share?

Pharmaceutical companies occupy lion’s share in the global market. The segment accounted for 42% market share in 2022. Pharmaceutical companies rely on market trends and intelligence to devise drug discovery strategies. They collaborate with research institutions and Contract Research Organizations (CROs) to research specific ailments for target audiences. Therefore, the increasing funding from pharmaceutical companies for new drug discoveries bolsters market growth. Moreover, the development and launch of novel drugs give a boost to market growth.

Which Process Segment is Dominant in Drug Discovery Services?

In terms of market share, the Hit-to-lead identification method is the dominant segment. A hit compound is a molecule that exhibits appropriate activity in a screening assay. Researchers use a slew of methods to find the hit molecule. Although, the conventional technique of high-throughput screening is the standard one. Therefore, the lead optimization segment is expected to see increased demand as technology advances and new state-of-the-art facilities arise.

Which Type of Drug Discovery Service Accounts for a Substantial Market Share?

The medicinal chemistry services segment is predicted to increase at a high-double-digit CAGR throughout the forecast period.

The trend of pharmaceutical companies outsourcing research and development services is growing. The expanding drug discovery and development activities and R&D investments are driving the market forward.

During the projection period, the biological services segment in the drug discovery market is expected to increase at a high CAGR.

Which Drug Type in Drug Discovery Services held a Sizable Market Share in 2022?

Small molecules accounted for a huge portion of the drug discovery services market in 2022. The biologics segment is predicted to expand at a remarkable CAGR in the coming years. The growing use of small-molecule medications to treat chronic diseases surges the demand for these drugs.

Small-molecule pharmaceuticals, even though, dominate the global pharmaceutical market, biologics, biosimilars, and large-molecule drugs are gaining market share. Primarily due to the introduction of new biologic-based treatments and rising earnings from current biologics. In addition, biologics and biosimilars necessitate more specialized testing services than small molecules at each level. Therefore, in the next few years, the growing demand for outsourcing these activities to CROs is likely to fuel the expansion of the market.

Which Therapeutic Area Segment Dominated the Global Drug Discovery Market?

Oncology dominated the drug discovery services market in terms of therapeutic areas. It is predicted to continue to do so throughout the forecast period. The segment accounted for an impressive 39.7% market share in 2022. Cancer medicines are in high demand due to increasing cancer cases worldwide. This is likely to make the segment a prominent shareholder in the next years.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Comparative View of the Adjacent Market

Drug Discovery Services Market:

Attributes Drug Discovery Services Market
CAGR (2023 to 2033) 14.5%
Market Value (2023) US$ 19.7 billion
Growth Factor Surging demand for new drugs to cater to unmet medical needs.
Future Opportunities Discovery and development of novel drugs.
Market Trends Increasing investments and expansion of production capacities.

Computer-aided Drug Discovery Market:

Attributes Computer-aided Drug Discovery Market
CAGR (2023 to 2033) 15.2%
Market Value (2023) US$ 5.17 billion
Growth Factor Increasing the cost-efficiency of the drug development process to boost adoption.
Future Opportunities Availability of high-end software and progressive improvement in their efficiency.
Market Trends Strategic partnerships and collaborations for product innovation are a go-to-market move.

Artificial Intelligence in Drug Discovery Market:

Attributes Artificial Intelligence in Drug Discovery Market
CAGR (2023 to 2033) 40.2%
Market Value (2023) US$ 1.82 billion
Growth Factor Growing adoption of innovative drug development processes to reduce market times.
Future Opportunities Increasing demand for novel drugs.
Market Trends Expansion of production capabilities.

There are a few significant factors that limit the market’s growth. The need for a substantial capital investment with low-profit margins hinders market development. A comparatively inadequate healthcare system in middle-income and low-income nations impedes the drug discovery and development process.

The drug discovery services sector continues to remain heavily regulated. This makes the operations complex and removes the layer of adaptability. The years- to decades-long operation can be complicated in the continuous adoption of drug discovery services. There is almost always a chance that medicine may fail to advance to the next stage of research. The lack of predictive accuracy of current animal studies and high drug development costs affect growth prospects. Limited knowledge of underlying illness mechanics, patient diversity, and a lack of endpoints and biomarkers amplify these issues. A high proportion of failed drug trials and legislative obstacles are all constraints that this long research pathway encounters.

Country-wise Insights

Why Does North America Dominate Global Market Share?

North America is a global leader in research and development spending in the pharmaceutical industry. The region accounted for a massive 35.2% market share in 2022. The region is also an outsize market for bulk medications and ready-to-use dosage forms.

The United States accounted for 24.1% market share in 2022. The region’s market works as a free economy, with transparent trading practices and anti-competitive actions restricted. Since biologics is more expensive, the United States has a lot of room for biosimilars. As a result, the United States drug discovery services market is one of the primary competitors for biosimilars.

Remicade, Enbrel, Rituximab, Adalimumab, Infliximab, Etanercept, Darbepoetin Alpha, and other drugs are among the popular players in the United States. As a result of the factors mentioned above, the market is expected to grow rapidly over the forecast period. The progressive increase in regional healthcare spending aids new pharmaceutical technology advancements.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Which Growth Strategies are Likely to be Adopted by Market Players?

The global drug discovery services market is competitive, with Laboratory Corporation of America Holdings (United States), Charles River Laboratories International Inc. (United States), WuXi AppTec (China), and Thermo Fisher Scientific Inc. (United States) collectively accounting for a large portion of the market. The United States-based company, Laboratory Corporation of America Holdings, is a prominent player in the global market.

These key players in the global drug discovery market focus on a broad spectrum of clients. They emphasize incorporating modern and advanced technology-enabled solutions. Increasing investments in joint ventures & partnerships are likely to be prevalent as key strategies. Extensive quality systems and processes contribute to the growth of businesses operating in the market. These companies may use organic and inorganic growth techniques, such as acquisitions and expansions, to tap into new demographics.

Several drugs are pending approval from the United States Food and Drug Administration (FDA).

Anticipated Drug Approvals in 2023:

  • In January 2023, Genentech declared that it received a Priority Review and Fast Track designation grant for Glofitamab. The drug is a novel bispecific antibody that engages T-cells of the immune system to treat adult patients with refractory or relapsed LBCL.
  • In January 2023, Brexpiprazole, an atypical antipsychotic supplement NDA approved for schizophrenia was put under Priority Review by FDA. Brexpiprazole is a drug developed by H. Lundbeck A/S and Otsuka Pharmaceuticals.
  • In January 2023, UCB’s Rozanolixizumab was accepted by the FDA for further Phase III study.
  • In December 2022, Harm Reduction Therapeutics announced that FDA accepted and granted Priority for Review to their NDA for RiVive. The product is an over-the-counter naloxone nasal spray.

Key Players in the Market

  • Laboratory Corporation of America Holdings
  • Charles River Laboratories International Inc.
  • Genscript Biotech Corporation
  • Thermo Fisher Scientific Inc.
  • Pharmaron Beijing Co. Ltd.
  • Evotec SE
  • Eurofins Scientific SE
  • Pharmaceutical Product Development Inc.
  • Piramal Enterprise Limited
  • Syngene International Limited

Market Segmentation

By Process:

  • Target Selection
  • Target Validation
  • Hit-to-lead identification
  • Lead Optimization
  • Candidate Validation

By Type:

  • Chemistry Services
  • Biology Services

By Drug Type:

  • Small Molecule Drugs
  • Biologics Drugs

By Therapeutic Area:

  • Neurology
  • Infectious and Immune Systems Diseases
  • Digestive System Diseases
  • Oncology
  • Other Therapeutic Areas

By End User:

  • Pharmaceutical & Biotechnology Companies
  • Academic Institutes
  • Manufacturing
  • Other End Users

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • The Middle East & Africa

Frequently Asked Questions

How Big Was the Drug Discovery Services Market in 2022?

The market attained a revenue of US$ 17.5 billion in 2022.

What is the Key Trend Driving Market Growth?

Increasing funding and reimbursement initiatives increases market demand.

Which End-use Industry Holds Lucrative Opportunities?

Pharmaceutical companies offer lucrative opportunities.

Which Process Segment is Dominant in Drug Discovery Services?

The hit-to-lead identification method is the dominant segment.

What is the Current Market Valuation?

The market is estimated to secure a valuation of US$ 19.7 billion in 2023.

Table of Content

1. Executive Summary | Drug Discovery Services Market 

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Process

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Process, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Process, 2023 to 2033

        5.3.1. Target Selection

        5.3.2. Target Validation

        5.3.3. Hit-to-Lead Identification

        5.3.4. Lead Optimization

        5.3.5. Candidate Validation

    5.4. Y-o-Y Growth Trend Analysis By Process, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Process, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033

        6.3.1. Chemistry Services

        6.3.2. Biology Services

    6.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033

        7.3.1. Small Molecules Drugs

        7.3.2. Biologics Drugs

    7.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutic Area

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Million) Analysis By Therapeutic Area, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapeutic Area, 2023 to 2033

        8.3.1. Neurology

        8.3.2. Infectious and Immune System Diseases

        8.3.3. Digestive System Diseases

        8.3.4. Oncology

        8.3.5. Other Therapeutic Area

    8.4. Y-o-Y Growth Trend Analysis By Therapeutic Area, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By Therapeutic Area, 2023 to 2033

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    9.1. Introduction / Key Findings

    9.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

    9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        9.3.1. Pharmaceutical & Biotechnology Companies

        9.3.2. Academic Institutes

        9.3.3. Manufacturing

        9.3.4. Other End Users

    9.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    9.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    10.1. Introduction

    10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. South Asia

        10.3.5. East Asia

        10.3.6. Oceania

        10.3.7. MEA

    10.4. Market Attractiveness Analysis By Region

11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. The USA

            11.2.1.2. Canada

        11.2.2. By Process

        11.2.3. By Type

        11.2.4. By Drug Type

        11.2.5. By Therapeutic Area

        11.2.6. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Process

        11.3.3. By Type

        11.3.4. By Drug Type

        11.3.5. By Therapeutic Area

        11.3.6. By End User

    11.4. Key Takeaways

12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Brazil

            12.2.1.2. Mexico

            12.2.1.3. Rest of Latin America

        12.2.2. By Process

        12.2.3. By Type

        12.2.4. By Drug Type

        12.2.5. By Therapeutic Area

        12.2.6. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Process

        12.3.3. By Type

        12.3.4. By Drug Type

        12.3.5. By Therapeutic Area

        12.3.6. By End User

    12.4. Key Takeaways

13. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Germany

            13.2.1.2. United Kingdom

            13.2.1.3. France

            13.2.1.4. Spain

            13.2.1.5. Italy

            13.2.1.6. Rest of Europe

        13.2.2. By Process

        13.2.3. By Type

        13.2.4. By Drug Type

        13.2.5. By Therapeutic Area

        13.2.6. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Process

        13.3.3. By Type

        13.3.4. By Drug Type

        13.3.5. By Therapeutic Area

        13.3.6. By End User

    13.4. Key Takeaways

14. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. India

            14.2.1.2. Malaysia

            14.2.1.3. Singapore

            14.2.1.4. Thailand

            14.2.1.5. Rest of South Asia

        14.2.2. By Process

        14.2.3. By Type

        14.2.4. By Drug Type

        14.2.5. By Therapeutic Area

        14.2.6. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Process

        14.3.3. By Type

        14.3.4. By Drug Type

        14.3.5. By Therapeutic Area

        14.3.6. By End User

    14.4. Key Takeaways

15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. China

            15.2.1.2. Japan

            15.2.1.3. South Korea

        15.2.2. By Process

        15.2.3. By Type

        15.2.4. By Drug Type

        15.2.5. By Therapeutic Area

        15.2.6. By End User

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Process

        15.3.3. By Type

        15.3.4. By Drug Type

        15.3.5. By Therapeutic Area

        15.3.6. By End User

    15.4. Key Takeaways

16. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. Australia

            16.2.1.2. New Zealand

        16.2.2. By Process

        16.2.3. By Type

        16.2.4. By Drug Type

        16.2.5. By Therapeutic Area

        16.2.6. By End User

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Process

        16.3.3. By Type

        16.3.4. By Drug Type

        16.3.5. By Therapeutic Area

        16.3.6. By End User

    16.4. Key Takeaways

17. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        17.2.1. By Country

            17.2.1.1. GCC Countries

            17.2.1.2. South Africa

            17.2.1.3. Israel

            17.2.1.4. Rest of MEA

        17.2.2. By Process

        17.2.3. By Type

        17.2.4. By Drug Type

        17.2.5. By Therapeutic Area

        17.2.6. By End User

    17.3. Market Attractiveness Analysis

        17.3.1. By Country

        17.3.2. By Process

        17.3.3. By Type

        17.3.4. By Drug Type

        17.3.5. By Therapeutic Area

        17.3.6. By End User

    17.4. Key Takeaways

18. Key Countries Market Analysis

    18.1. USA

        18.1.1. Pricing Analysis

        18.1.2. Market Share Analysis, 2022

            18.1.2.1. By Process

            18.1.2.2. By Type

            18.1.2.3. By Drug Type

            18.1.2.4. By Therapeutic Area

            18.1.2.5. By End User

    18.2. Canada

        18.2.1. Pricing Analysis

        18.2.2. Market Share Analysis, 2022

            18.2.2.1. By Process

            18.2.2.2. By Type

            18.2.2.3. By Drug Type

            18.2.2.4. By Therapeutic Area

            18.2.2.5. By End User

    18.3. Brazil

        18.3.1. Pricing Analysis

        18.3.2. Market Share Analysis, 2022

            18.3.2.1. By Process

            18.3.2.2. By Type

            18.3.2.3. By Drug Type

            18.3.2.4. By Therapeutic Area

            18.3.2.5. By End User

    18.4. Mexico

        18.4.1. Pricing Analysis

        18.4.2. Market Share Analysis, 2022

            18.4.2.1. By Process

            18.4.2.2. By Type

            18.4.2.3. By Drug Type

            18.4.2.4. By Therapeutic Area

            18.4.2.5. By End User

    18.5. Germany

        18.5.1. Pricing Analysis

        18.5.2. Market Share Analysis, 2022

            18.5.2.1. By Process

            18.5.2.2. By Type

            18.5.2.3. By Drug Type

            18.5.2.4. By Therapeutic Area

            18.5.2.5. By End User

    18.6. United Kingdom

        18.6.1. Pricing Analysis

        18.6.2. Market Share Analysis, 2022

            18.6.2.1. By Process

            18.6.2.2. By Type

            18.6.2.3. By Drug Type

            18.6.2.4. By Therapeutic Area

            18.6.2.5. By End User

    18.7. France

        18.7.1. Pricing Analysis

        18.7.2. Market Share Analysis, 2022

            18.7.2.1. By Process

            18.7.2.2. By Type

            18.7.2.3. By Drug Type

            18.7.2.4. By Therapeutic Area

            18.7.2.5. By End User

    18.8. Spain

        18.8.1. Pricing Analysis

        18.8.2. Market Share Analysis, 2022

            18.8.2.1. By Process

            18.8.2.2. By Type

            18.8.2.3. By Drug Type

            18.8.2.4. By Therapeutic Area

            18.8.2.5. By End User

    18.9. Italy

        18.9.1. Pricing Analysis

        18.9.2. Market Share Analysis, 2022

            18.9.2.1. By Process

            18.9.2.2. By Type

            18.9.2.3. By Drug Type

            18.9.2.4. By Therapeutic Area

            18.9.2.5. By End User

    18.10. India

        18.10.1. Pricing Analysis

        18.10.2. Market Share Analysis, 2022

            18.10.2.1. By Process

            18.10.2.2. By Type

            18.10.2.3. By Drug Type

            18.10.2.4. By Therapeutic Area

            18.10.2.5. By End User

    18.11. Malaysia

        18.11.1. Pricing Analysis

        18.11.2. Market Share Analysis, 2022

            18.11.2.1. By Process

            18.11.2.2. By Type

            18.11.2.3. By Drug Type

            18.11.2.4. By Therapeutic Area

            18.11.2.5. By End User

    18.12. Singapore

        18.12.1. Pricing Analysis

        18.12.2. Market Share Analysis, 2022

            18.12.2.1. By Process

            18.12.2.2. By Type

            18.12.2.3. By Drug Type

            18.12.2.4. By Therapeutic Area

            18.12.2.5. By End User

    18.13. Thailand

        18.13.1. Pricing Analysis

        18.13.2. Market Share Analysis, 2022

            18.13.2.1. By Process

            18.13.2.2. By Type

            18.13.2.3. By Drug Type

            18.13.2.4. By Therapeutic Area

            18.13.2.5. By End User

    18.14. China

        18.14.1. Pricing Analysis

        18.14.2. Market Share Analysis, 2022

            18.14.2.1. By Process

            18.14.2.2. By Type

            18.14.2.3. By Drug Type

            18.14.2.4. By Therapeutic Area

            18.14.2.5. By End User

    18.15. Japan

        18.15.1. Pricing Analysis

        18.15.2. Market Share Analysis, 2022

            18.15.2.1. By Process

            18.15.2.2. By Type

            18.15.2.3. By Drug Type

            18.15.2.4. By Therapeutic Area

            18.15.2.5. By End User

    18.16. South Korea

        18.16.1. Pricing Analysis

        18.16.2. Market Share Analysis, 2022

            18.16.2.1. By Process

            18.16.2.2. By Type

            18.16.2.3. By Drug Type

            18.16.2.4. By Therapeutic Area

            18.16.2.5. By End User

    18.17. Australia

        18.17.1. Pricing Analysis

        18.17.2. Market Share Analysis, 2022

            18.17.2.1. By Process

            18.17.2.2. By Type

            18.17.2.3. By Drug Type

            18.17.2.4. By Therapeutic Area

            18.17.2.5. By End User

    18.18. New Zealand

        18.18.1. Pricing Analysis

        18.18.2. Market Share Analysis, 2022

            18.18.2.1. By Process

            18.18.2.2. By Type

            18.18.2.3. By Drug Type

            18.18.2.4. By Therapeutic Area

            18.18.2.5. By End User

    18.19. GCC Countries

        18.19.1. Pricing Analysis

        18.19.2. Market Share Analysis, 2022

            18.19.2.1. By Process

            18.19.2.2. By Type

            18.19.2.3. By Drug Type

            18.19.2.4. By Therapeutic Area

            18.19.2.5. By End User

    18.20. South Africa

        18.20.1. Pricing Analysis

        18.20.2. Market Share Analysis, 2022

            18.20.2.1. By Process

            18.20.2.2. By Type

            18.20.2.3. By Drug Type

            18.20.2.4. By Therapeutic Area

            18.20.2.5. By End User

    18.21. Israel

        18.21.1. Pricing Analysis

        18.21.2. Market Share Analysis, 2022

            18.21.2.1. By Process

            18.21.2.2. By Type

            18.21.2.3. By Drug Type

            18.21.2.4. By Therapeutic Area

            18.21.2.5. By End User

19. Market Structure Analysis

    19.1. Competition Dashboard

    19.2. Competition Benchmarking

    19.3. Market Share Analysis of Top Players

        19.3.1. By Regional

        19.3.2. By Process

        19.3.3. By Type

        19.3.4. By Drug Type

        19.3.5. By Therapeutic Area

        19.3.6. By End User

20. Competition Analysis

    20.1. Competition Deep Dive

        20.1.1. Laboratory Corporation of America Holdings

            20.1.1.1. Overview

            20.1.1.2. Product Portfolio

            20.1.1.3. Profitability by Market Segments

            20.1.1.4. Sales Footprint

            20.1.1.5. Strategy Overview

                20.1.1.5.1. Marketing Strategy

        20.1.2. Charles River Laboratories International Inc.

            20.1.2.1. Overview

            20.1.2.2. Product Portfolio

            20.1.2.3. Profitability by Market Segments

            20.1.2.4. Sales Footprint

            20.1.2.5. Strategy Overview

                20.1.2.5.1. Marketing Strategy

        20.1.3. Genscript Biotech Corporation

            20.1.3.1. Overview

            20.1.3.2. Product Portfolio

            20.1.3.3. Profitability by Market Segments

            20.1.3.4. Sales Footprint

            20.1.3.5. Strategy Overview

                20.1.3.5.1. Marketing Strategy

        20.1.4. Thermo Fisher Scientific Inc.

            20.1.4.1. Overview

            20.1.4.2. Product Portfolio

            20.1.4.3. Profitability by Market Segments

            20.1.4.4. Sales Footprint

            20.1.4.5. Strategy Overview

                20.1.4.5.1. Marketing Strategy

        20.1.5. Pharmaron Beijing Co., Ltd.

            20.1.5.1. Overview

            20.1.5.2. Product Portfolio

            20.1.5.3. Profitability by Market Segments

            20.1.5.4. Sales Footprint

            20.1.5.5. Strategy Overview

                20.1.5.5.1. Marketing Strategy

        20.1.6. Evotec SE

            20.1.6.1. Overview

            20.1.6.2. Product Portfolio

            20.1.6.3. Profitability by Market Segments

            20.1.6.4. Sales Footprint

            20.1.6.5. Strategy Overview

                20.1.6.5.1. Marketing Strategy

        20.1.7. Eurofins Scientific SE

            20.1.7.1. Overview

            20.1.7.2. Product Portfolio

            20.1.7.3. Profitability by Market Segments

            20.1.7.4. Sales Footprint

            20.1.7.5. Strategy Overview

                20.1.7.5.1. Marketing Strategy

        20.1.8. Pharmaceutical Product Development, Inc.

            20.1.8.1. Overview

            20.1.8.2. Product Portfolio

            20.1.8.3. Profitability by Market Segments

            20.1.8.4. Sales Footprint

            20.1.8.5. Strategy Overview

                20.1.8.5.1. Marketing Strategy

        20.1.9. Piramal Enterprises Limited

            20.1.9.1. Overview

            20.1.9.2. Product Portfolio

            20.1.9.3. Profitability by Market Segments

            20.1.9.4. Sales Footprint

            20.1.9.5. Strategy Overview

                20.1.9.5.1. Marketing Strategy

        20.1.10. Syngene International Limited

            20.1.10.1. Overview

            20.1.10.2. Product Portfolio

            20.1.10.3. Profitability by Market Segments

            20.1.10.4. Sales Footprint

            20.1.10.5. Strategy Overview

                20.1.10.5.1. Marketing Strategy

21. Assumptions & Acronyms Used

22. Research Methodology

Recommendations

Healthcare

Drug Discovery Outsourcing Market

April 2023

REP-GB-16937

324 pages

Healthcare

Drug Discovery Informatics Market

January 2023

REP-GB-16381

250 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Drug Discovery Services Market